STARBORN-1: Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age

• Sponsor: Protara Therapeutics (Industry)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT05871970
• Collaborator: (none)
• Enrollment: 38
• Arm: 1
• Anticipated Duration (Months): 31

Study Details

Study Description

Brief Summary

This is a Phase 2a/b single arm open label study to evaluate the safety, reactogenicity, and efficacy of intracystic injection of TARA-002 in participants 6 months to less than 18 years of age for the treatment of macrocystic and mixed cystic lymphatic malformations. The Phase 2a safety lead-in, age de-escalation study is designed to establish the safety of TARA-002 in older participants 6 years to less than 18 years before proceeding to younger participants 2 years to less than 6 years, then 6 months to less than 2 years. The Phase 2b is an expansion study in which enrollment of participants will be initiated after safety has been established in each cohort during the Phase 2a safety lead-in study. Each participant will receive up to 4 injections of TARA-002 spaced approximately 6 weeks apart.

Condition or Disease	Intervention/Treatment	Phase
Lymphatic Malformation	Biological: TARA-002	Phase 2

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 38 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 2a/b Single Arm Open Label Study to Evaluate the Safety and Efficacy of Intracystic Administration of TARA-002 in Participants Between 6 Months to Less Than 18 Years of Age for the Treatment of Macrocystic and Mixed Cystic Lymphatic Malformations
• Anticipated Study Start Date: Oct 1, 2023
• Anticipated Primary Completion Date: Dec 1, 2025
• Anticipated Study Completion Date: May 1, 2026

Arms and Interventions

Arm	Intervention/Treatment
Experimental: TARA-002 TARA-002 is a lyophilized biological preparation for injection containing cells of Streptococcus pyogenes (Group A, type 3) Su strain treated with benzylpenicillin.	Biological: TARA-002; All participants will receive up to 4 intracystic injections spaced approximately 6 weeks apart.

Outcome Measures

Primary Outcome Measures

1. Proportion of participants with clinical success after one treatment cycle of TARA-002 [8 weeks after the last injection]

Secondary Outcome Measures

1. Safety: Percentage of participants with solicited local site and systemic reactions [14 days (2 weeks) after each injection]

2. Safety: Percentage of participants with unsolicited adverse events (AEs) [Through study completion (approximately 32 weeks after last injection)]

3. Safety: Percentage of participants with SAEs, AEs of special interest, AEs leading to premature discontinuation of study intervention, AEs leading to withdrawal from study, AEs with an outcome of death, and MAAEs [Through study completion (approximately 32 weeks after last injection)]

4. Durable Response: Proportion of participants with clinical success after one treatment cycle of TARA-002 assessed at 8 weeks after the last injection and maintained clinical success at 32 weeks after the last injection [32 weeks after the last injection]

5. Clinical Success by LM Type: Proportion of participants with macrocystic LM or mixed cystic LM with clinical success after one treatment cycle of TARA-002 [8 weeks after the last injection]

6. Investigator Assessment: Proportion of participants who demonstrate clinical improvement, as assessed by the Investigator, after one treatment cycle of TARA-002 compared to baseline [8 weeks after last injection and 32 weeks after last injection]

7. Quality of Life: Change in Quality-of-Life assessment based on Pediatric Quality of Life Inventory (PedsQL) and Visual Analog Scale (VAS) for Pain after one treatment cycle of TARA-002 [8 weeks after last injection and 32 weeks after last injection]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 6 Months to 18 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Male or female participants 6 months to less than 18 years of age at the time of informed consent/assent form was signed

• Participants whose parent/LAR(s) have voluntarily given written consent and participants who provided assent (if applicable) after the study has been explained to them

• Participants with macrocystic LM or mixed cystic LM (≥ 50% macrocystic disease measured by volume) of the Head/Neck/Mediastinum according to the ISSVA 2018 criteria (ISSVA 2018) measured via LM imaging at Screening to confirm, upon central review, the diagnosis of macrocystic or mixed cystic LM

• Participants who may have had surgical or sclerotherapy treatment for their LM, but not within six months of the consent/assent form being signed

Exclusion Criteria:

• Penicillin allergy

• Vascular tumors or combined vascular malformations

• Microcystic LM or mixed cystic LM with predominant microcystic features

• LMs of the orbit (orbital LM) as target cyst

For more information on eligibility criteria, please contact the sponsor.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• Protara Therapeutics

Investigators

• Study Director: Chief Scientific Operations Officer, Protara Therapeutics

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Protara Therapeutics
• ClinicalTrials.gov Identifier: NCT05871970
• Other Study ID Numbers: TARA-002-201
• First Posted: May 23, 2023
• Last Update Posted: May 23, 2023
• Last Verified: May 1, 2023

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Protara Therapeutics: Macrocystic lymphatic malformations; Mixed-cystic lymphatic malformations
• Additional relevant MeSH terms: Lymphangioma; Lymphatic Abnormalities; Congenital Abnormalities

Study Results

No Results Posted as of May 23, 2023